Biotech Values

[DewDiligence]

Agree. Teva’s sole 2015 Copaxone patent is a process patent*, so showing non-infringement to reverse the District Court’s ruling ought to be an easier task than reversing the ruling on most of Teva’s 2014 Copaxone patents.

*The reason it is not in the Orange Book.